Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111,967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S. Connolly RM, et al. Among authors: zhang z. Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16. Breast Cancer Res Treat. 2018. PMID: 28918548 Free PMC article. Clinical Trial.
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Lyman JP, de Brot M, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope L, Wolff AC, Sukumar S. Fackler MJ, et al. Among authors: zhang z. Cancer Res. 2014 Apr 15;74(8):2160-70. doi: 10.1158/0008-5472.CAN-13-3392. Cancer Res. 2014. PMID: 24737128 Free PMC article.
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V. Connolly RM, et al. Among authors: zhang z. J Nucl Med. 2015 Jan;56(1):31-7. doi: 10.2967/jnumed.114.144741. Epub 2014 Dec 4. J Nucl Med. 2015. PMID: 25476537 Free PMC article. Clinical Trial.
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V. Sheng JY, et al. Among authors: zhang z. Breast Cancer Res Treat. 2019 Aug;176(3):617-624. doi: 10.1007/s10549-019-05270-4. Epub 2019 May 11. Breast Cancer Res Treat. 2019. PMID: 31079282 Free PMC article.
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray JW, Wolff AC, Cope LM, Sukumar S. Fackler MJ, et al. Among authors: zhang z. Cancer Res. 2011 Oct 1;71(19):6195-207. doi: 10.1158/0008-5472.CAN-11-1630. Epub 2011 Aug 8. Cancer Res. 2011. PMID: 21825015 Free PMC article.
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. Bardia A, et al. Among authors: zhang z. Breast Cancer Res Treat. 2012 Feb;131(3):907-14. doi: 10.1007/s10549-011-1843-1. Epub 2011 Nov 1. Breast Cancer Res Treat. 2012. PMID: 22042368 Free PMC article. Clinical Trial.
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.
Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, Han L, Foster YMN, Zhou XC, Zhang Z, Connolly RM, Stearns V, Ali SZ, Adams C, Chen Q, Pan D, Huso DL, Ordentlich P, Brodie A, Sukumar S. Merino VF, et al. Among authors: zhang z. Cancer Res. 2016 Apr 1;76(7):2013-2024. doi: 10.1158/0008-5472.CAN-15-1619. Epub 2016 Jan 19. Cancer Res. 2016. PMID: 26787836 Free PMC article.
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.
Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH. Parsons HA, et al. Among authors: zhang z. Clin Cancer Res. 2017 Jan 15;23(2):379-386. doi: 10.1158/1078-0432.CCR-16-1543. Epub 2016 Aug 3. Clin Cancer Res. 2017. PMID: 27489289 Free PMC article.
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC. Visvanathan K, et al. Among authors: zhang z. J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21. J Clin Oncol. 2017. PMID: 27870562 Free PMC article.
111,967 results
You have reached the last available page of results. Please see the User Guide for more information.